Skip to main content
Clinical Trials/NCT04353583
NCT04353583
Completed
Not Applicable

Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) in Patients With Coronavirus Disease 2019 (COVID-19)

University of Giessen1 site in 1 country900 target enrollmentApril 21, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Kidney Injury
Sponsor
University of Giessen
Enrollment
900
Locations
1
Primary Endpoint
Incidence of AKI
Status
Completed
Last Updated
last year

Overview

Brief Summary

Acute kidney injury (AKI) has been identified as an independent risk factor for in-hospital mortality. The present study aims to investigate the incidence of AKI and renal recovery of inpatients diagnosed with COVID-19.

Detailed Description

Beginning in December 2019, a novel coronavirus, designated as severe acute respiratory distress coronavirus 2 (SARS-CoV-2), has caused an international outbreak of respiratory illness termed coronavirus disease 2019 (COVID-19). Although the clinical manifestations of COVID-19 are dominated by respiratory symptoms, some patients show severe kidney abnormalities. Acute kidney injury (AKI) has been identified as an independent risk factor for in-hospital mortality. The present study aims to investigate the incidence of AKI and renal recovery of inpatients diagnosed with COVID-19.

Registry
clinicaltrials.gov
Start Date
April 21, 2020
End Date
February 1, 2025
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with COVID-19 diagnosed by World Health Organisation (WHO) criteria

Exclusion Criteria

  • Patients aged less than 18 years
  • Patients with stage 4 chronic kidney disease (baseline estimated glomerular filtration rate \<30 ml/min/1.73 m2)
  • Patients receiving maintenance dialysis
  • Recipients of solid-organ transplantation

Outcomes

Primary Outcomes

Incidence of AKI

Time Frame: 30 days post-hospital admission

Serial assessment of serum creatinine and urine output

Cystatin C as indicator of mortality

Time Frame: 30 days post-hospital admission

All-cause mortality

Cystatin C as indicator of renal disease

Time Frame: 30 days post-hospital admission

AKI and acute kidney disease (AKD)

Cystatin C as indicator of disease severity

Time Frame: 30 days post-hospital admission

Rate of intensive care unit admission

Cystatin C as indicator of respiratory illness

Time Frame: 30 days post-hospital admission

Ventilator-free days

Study Sites (1)

Loading locations...

Similar Trials